Epigenetic inactivation of the autophagy-lysosomal system in appendix in Parkinson’s disease

Juozas Gordevicius 1,2✉, Peipei Li 1, Lee L. Marshall 1, Bryan A. Killinger 1,3, Sean Lang 1, Elizabeth Ensink 1, Nathan C. Kuhn 4, Wei Cui 5, Nazia Maroof 6, Roberta Lauria 6, Christina Rueb 6, Juliane Siebourg-Polster 7, Pierre Maliver 7, Jared Lamp 4,8, Irving Vega 4,8, Fredric P. Manfredsson 4,9, Markus Britschgi 6 & Viviane Labrie 1,10

The gastrointestinal tract may be a site of origin for α-synuclein pathology in idiopathic Parkinson’s disease (PD). Disruption of the autophagy-lysosome pathway (ALP) may contribute to α-synuclein aggregation. Here we examined epigenetic alterations in the ALP in the appendix by deep sequencing DNA methylation at 521 ALP genes. We identified aberrant methylation at 928 cytosines affecting 326 ALP genes in the appendix of individuals with PD and widespread hypermethylation that is also seen in the brain of individuals with PD. In mice, we find that DNA methylation changes at ALP genes induced by chronic gut inflammation are greatly exacerbated by α-synuclein pathology. DNA methylation changes at ALP genes induced by synucleinopathy are associated with the ALP abnormalities observed in the appendix of individuals with PD specifically involving lysosomal genes. Our work identifies epigenetic dysregulation of the ALP which may suggest a potential mechanism for accumulation of α-synuclein pathology in idiopathic PD.

https://doi.org/10.1038/s41467-021-25474-x

1 Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA. 2 Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania. 3 Graduate College, Rush University Medical Center, Chicago, IL, USA. 4 Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA. 5 Center for Epigenetics, Van Andel Institute, Grand Rapids, MI, USA. 6 Roche Pharma Research and Early Development, Neuroscience Discovery, Roche Innovation Center, Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. 7 Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. 8 Integrated Mass Spectrometry Unit, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA. 9 Parkinson’s Disease Research Unit, Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA. 10 Division of Psychiatry and Behavioral Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA. ✉email: juozas.gordevicius@vai.org
Parkinson’s disease (PD) is a common neurodegenerative movement disorder affecting approximately 1% of individuals over the age of 60. Clinically, PD is characterized by both motor and non-motor symptoms. Non-motor symptoms, such as gastrointestinal (GI) dysfunction, may appear as many as 20 years prior to motor symptoms, during the prodromal phase of the disease. Intraneuronal alpha-synuclein (α-syn) aggregates, the pathological hallmark of PD, have been detected in GI tract neurons of individuals in the prodromal stage of PD. Development of pathological α-syn inclusions in neurons and loss of neuronal function is hypothesized to occur by a neuron-to-neuron propagation of presumably aggregated toxic species of α-syn. Because α-syn aggregates are detected in the GI tract early in disease and, in animal models of synucleinopathy, the pathology is capable of propagating to the brain via the vagus nerve, it has been suggested that the GI tract may be a point of origin for idiopathic PD. We recently demonstrated that the appendix hosts an abundance of aggregated α-syn in healthy individuals and PD patients, with the PD appendix showing a greater amount of insoluble α-syn. Hence, the appendix may be a source of α-syn pathology that contributes to the initiation of PD. However, the presence of α-syn aggregates in the healthy human appendix suggests that these aggregates in the gut are not implicitly disease-causing. Rather, there must be another molecular system whose dysfunction enables the accumulation of α-syn aggregates and their propagation to the brain.

Dysfunction of the autophagy–lysosomal pathway (ALP) may play a key role in the pathogenesis of PD. The ALP is responsible for the degradation of intracellular structures such as organelles or aggregated proteins, including α-syn. The ALP is compromised in PD, and its disruption in neurons causes an accumulation of aggregation-prone α-syn and subsequent neurodegeneration. Inhibition of the ALP also promotes the extracellular release of α-syn aggregates via exosomes that are capable of interneuronal travel, thereby facilitating the spread of α-syn pathology. Many genes implicated in PD by GWAS and transcriptomic studies are linked to ALP function, including the most common monogenetic causes of PD.

Furthermore, decreasing activity of the ALP is closely related to aging, which itself is the strongest risk factor for idiopathic PD. Taken together, the apparent relationships among PD, the ALP, and the development and spread of α-syn pathology suggest that disruption of the ALP in the aging appendix could be an important mechanism underlying the transfer of α-syn aggregates from the appendix to brain in PD. However, little is known about the mechanisms underlying the development of α-syn pathology in the gut or what triggers its spread to the brain.

There is evidence that epigenetic perturbation of the ALP could be responsible. DNA methylation is an epigenetic mark that is key to the regulation of gene expression, cellular function, and phenotypic outcome. DNA methylation is known to regulate the activity of ALP genes. Epigenetically mediated gene silencing has been shown to control autophagic flux and the supply of autophagy-related proteins. Furthermore, changes in DNA methylation facilitate the decline in autophagic activity with age. Epigenetic remodeling is known to occur with aging and linked to neurodegeneration. Accelerated DNA methylation changes with age. Thus, DNA methylation changes at ALP genes could be responsible for the impaired clearance, accumulation, and spread of aggregated α-syn in PD.

In this study, we perform a comprehensive fine-mapping of DNA methylation across all genes involved in the ALP (521 genes reported in publicly available human autophagy and lysosomal databases as well as PD risk genes). We first determine DNA methylation abnormalities at ALP genes in the appendix of PD cases relative to controls. We then identify whether similar changes are mirrored in neurons of the prefrontal cortex, a region affected in later disease stages, and the olfactory bulb, another proposed starting point for PD. Next, we examine the effects of age on DNA methylation at the 521 ALP genes in the appendix and prefrontal cortex neurons of PD cases and controls. We also determine the relevance of gut inflammation and α-syn pathology in the mouse cecal patch to the ALP disruption observed in PD. We find a widespread epigenetic silencing of the ALP in the PD appendix, particularly among genes implicated in lysosomal function. DNA methylation-mediated inactivation of ALP genes may contribute to the impaired clearance of pathogenic α-syn in the appendix of PD patients.

**Results**

**Epigenetic dysregulation of the ALP in the PD appendix.** To determine whether epigenetic disruption of the ALP in the appendix could contribute to PD, we profiled DNA methylation at 521 genes involved in the ALP. The genes profiled were those reported on the Human Autophagy Database and Human Lysosome Gene Database, as well as PD risk genes, which have been implicated in ALP dysregulation. DNA methylation was comprehensively examined at each ALP gene and the surrounding area (± 300 kb) in the appendix of 24 PD patients and 19 controls (Supplementary Fig. 1). Fine-mapping of DNA methylation at ALP genes was performed using a targeted bisulfite sequencing approach involving a library of 67,789 unique probes, which after data preprocessing interrogated a total of 182,024 CpG methylation sites. Our analysis of differential methylation in the PD appendix was controlled for sample age, sex, postmortem interval, batch, and other sources of variation using vectors from a surrogate variable analysis. The surrogate variable analysis is a benchmark approach that corrects for cell-type heterogeneity and effectively removes other sources of variation.

DNA methylation abnormalities were detected at 928 cytosine sites affecting 326 ALP genes in the PD appendix relative to the control appendix (2.8 differentially methylated sites per affected ALP gene with 7% average methylation change; \(q < 0.05\), robust linear regression; 192 and 134 genes had more hypermethylated and hypomethylated cytosines, respectively; Fig. 1a; Supplementary Data 1). Assessment of all differentially methylated cytosines demonstrated a widespread hypermethylation of ALP gene regions in the PD appendix compared to controls (odds ratio (OR), measuring the magnitude of enrichment = 1.39, \(p = 1.05 \times 10^{-6}\), Fisher’s exact test; Fig. 1b). Interestingly, we observed an epigenetic dysregulation of genes implicated in PD risk by large meta-analyses of genome-wide association studies (GWAS). This included a hypomethylation (associated with epigenetic activation) of α-syn (SNCA) \((q < 0.05\), robust linear regression; Fig. 1a). There was also a hypermethylation (associated with epigenetic silencing) of Toll-like receptor 9 (TLR9), which controls host immune responses to pathogens via the lysosome; a hypermethylation of GTP cyclohydrolase 1 (GCH1), which regulates lysosomal function, dopamine synthesis, and infection; and a hypermethylation of glycophorin non-metastatic melanoma protein B (GPNNB), which attenuates inflammation \((q < 0.05\), robust linear regression; Fig. 1a). Since we profiled ALP genes and extended genomic areas that include enhancers, CpG islands, and other regulatory elements, we sought to determine the types of genomic regions with the most prominent epigenetic dysregulation. Promoters and CpG islands within ALP gene areas were most epigenetically perturbed in the PD appendix (OR = 3.55, \(p = 1.71 \times 10^{-45}\) and OR = 5.79,
Fig. 1 Epigenetic dysregulation of the ALP in the PD appendix, particularly at lysosomal genes. DNA methylation was fine-mapped at 521 genes in the ALP in the appendix of PD patients and controls (n = 24 and 19 individuals, respectively). a Manhattan plot demonstrating differential methylation in PD appendix. There were 326 genes in the ALP exhibiting differential methylation in PD relative to controls (928 cytosine sites at q < 0.05, robust linear regression). Highlighted are genes implicated in both our study and PD GWAS. Signed log p refers to the significance of differentially methylated cytosines, with sign corresponding to the direction of DNA methylation change (hypermethylation, green or hypomethylated, blue). Fisher regression). Highlighted are genes implicated in both our study and PD GWAS. b Fraction of significantly hypomethylated (blue) and hypermethylated (green) sites in the PD appendix, as compared to all sites (gray). P-value represents two-sided Fisher’s exact test for enrichment of hypermethylated sites among significant versus non-significant cytosines. c Genomic elements enriched with significant differentially methylated sites in the PD appendix. Filled circles represent *p < 0.05, **p < 0.01, and ***p < 0.001, two-sided Fisher’s exact test on n = 182,024 cytosines comparing the odds of observing significant cytosines within versus outside of the genomic element. Error bars indicate 95% confidence intervals. d ALP pathways enriched with differential methylation and differential gene expression. Filled bars represent *p < 0.05 and ***p < 0.001, two-sided Fisher’s exact test comparing the odds of observing significant cytosines at genes belonging to the selected pathway versus the other targeted ALP genes. e Pathways affected by transcriptomic changes in the PD appendix. Pathways for the differentially expressed genes in the PD appendix were obtained using DAVID and visualized with EnrichmentMap and AutoAnnotate in Cytoscape (v3.7.1). Node colors represent normalized enrichment score, where darker red signifies greater enrichment. Actual p values are reported in Supplementary Data 21.

\[ p = 3.20 \times 10^{-70} \text{, respectively; Fisher’s exact test; Fig. 1c).} \]

Furthermore, we identified active enhancers, poised enhancers, and active promoters in the healthy appendix by chromatin immunoprecipitation of histone H3K27ac and H3K4me1 marks (n = 3 individuals per mark). In ALP gene regions, DNA methylation abnormalities strongly affected active promoters and to a lesser extent affected active enhancers (OR = 4.88, \[ p = 1.24 \times 10^{-69} \] and OR = 1.39, \[ p = 5.98 \times 10^{-5} \]; Fisher’s exact test; Fig. 1c). We also confirmed that promoters at ALP genes had the strongest enrichment in hypermethylated cytosines (OR = 9.78, \[ p = 7.45 \times 10^{-111} \]; Fisher’s exact test; Supplementary Fig. 2). Hence, there is an epigenetic silencing of ALP gene areas that primarily impacts promoter activity.

We next sought to determine the ALP pathways that exhibited the most prominent epigenetic dysregulation in the PD appendix. We stratified the profiled ALP genes according to their corresponding pathways (gene ontology classifications) and found that lysosomal genes were enriched with hypermethylated cytosines in the PD appendix (OR = 1.33, \[ p = 9.80 \times 10^{-4} \]; Fisher’s exact test; Supplementary Fig. 3). Conversely, we found enrichment of hypomethylated cytosines among genes involved in autophagy (OR = 1.25; \[ p = 0.04 \]; Supplementary Fig. 3). Furthermore, there was an enrichment of DNA methylation alterations within 20 kb of lysosomal gene start sites in the PD appendix (OR = 2.12, \[ p = 3.67 \times 10^{-8} \]; Fisher’s exact test; Supplementary Fig. 4). DNA methylation changes in the PD appendix were specific to lysosomal genes, as no enrichment was observed for non-lysosomal genes profiled in this study (Supplementary Fig. 4). Hence, DNA methylation abnormalities in the ALP of the PD appendix particularly affect lysosomal genes.

To determine whether differential methylation of ALP genes corresponded to functionally relevant changes in gene transcript levels, we performed a transcriptomic analysis of the PD and control appendix by RNA sequencing (RNA-seq; n = 12 PD and 16 controls; Supplementary Fig. 1). Differentially expressed genes in the PD appendix were identified, after adjusting for sample age, sex, postmortem interval, RIN, and other sources of variation (including cell-type heterogeneity) using vectors from a surrogate variable analysis. We identified 246 genes with differential transcript levels in the PD appendix (q < 0.05, robust linear regression; Supplementary Data 2). There was no dominant direction of change transcriptome-wide, but ALP gene transcripts showed an overall downregulation (OR = 2.95, \[ p = 0.002 \], Fisher’s
Epigenetic dysregulation of the ALP is recapitulated in the PD brain. We investigated the extent to which DNA methylation abnormalities affecting the PD appendix are observed in the brain. In addition to the gut, the olfactory bulb has also been proposed as an initiation site for PD.41,42 We fine-mapped DNA methylation in the olfactory bulb of PD patients and controls (n = 9 PD and 14 controls) at the same 521 ALP genes and surrounding genomic area (± 300 kb) as for the appendix study and using the same bisulfite padlock probe approach (Supplementary Fig. 1). In olfactory bulb tissue, we interrogated DNA methylation at 143,553 CpG sites at ALP genes. We also profiled DNA methylation at ALP genes in neurons isolated from the prefrontal cortex of PD patients and controls (n = 52 PD patients and 42 controls; Supplementary Fig. 1). In isolated neurons, DNA methylation occurs at both CpG and CpH (i.e., CpA, CpT, CpC) locations,36 and thus in neurons of the prefrontal cortex, we investigated a total of 130,733 CpG and 696,665 CpH sites at ALP genes. Our analysis identified DNA methylation differences in the PD brain after adjusting for age, sex, postmortem interval, and, for prefrontal cortex neurons, the proportion of glutamate neurons to GABAergic neurons.52

In the olfactory bulb, we identified 1,142 differentially methylated cytosines affecting 353 genes in PD relative to controls (3.2 differentially methylated sites per affected ALP gene with 18% average methylation change; q < 0.05, robust linear regression; Fig. 2a; Supplementary Data 3). As observed in the PD appendix, there was a significant hypermethylation of ALP genes in the PD olfactory bulb (OR = 1.18, p = 0.006; Fisher’s exact test; Fig. 2b, OFB). In prefrontal cortex neurons, we observed 70 differentially methylated sites affecting 58 genes in PD (1.2 differentially methylated sites per affected ALP gene with average methylation change 8% in CpG and 6% in CpH sites; q < 0.05, robust linear regression; Fig. 2a; Supplementary Data 4), which again were mostly hypermethylated (OR = 2.41, p = 7.13 × 10⁻⁴, Fisher’s exact test; Fig. 2b, OFC). Specifically, we observed a strong hypermethylation trend among CT and CA dinucleotides (OR = 5.01, p = 0.005, OR = 13.41, p = 0.0004, respectively; Fisher’s exact test). We found a significant overlap between the ALP genes epigenetically disrupted in the PD appendix and those altered in the PD olfactory bulb and prefrontal cortex neurons (n = 264 overlapping genes, OR = 3.97, p = 2.39 × 10⁻¹¹ and n = 49 overlapping genes, OR = 5.20, p = 0.001, respectively, Fisher’s exact test). Similar disruptions of PD risk genes to those identified in the PD appendix included aberrant TLR9 methylation, GPNMB hypermethylation, and SNCA hypomethylation in the analyzed PD brain regions (Supplementary Figs. 5 and S6). We also examined prefrontal cortex neurons of PD patients that did not have Lewy pathology (Braak stage 3–4) and identified 110 differentially methylated cytosines affecting 87 genes relative to controls (q < 0.05, robust linear regression; n = 20 PD Braak stage 3–4, 42 controls; Supplementary Data 5). These changes significantly overlapped with those identified with the full cohort (OR = 349.36, p = 1.24 × 10⁻⁷, Fisher’s exact test), suggesting that many of the DNA methylation changes observed precede the onset of Lewy pathology.

We further confirmed our findings in the PD brain using a separate cohort of neurons isolated from the prefrontal cortex. Since this was a smaller cohort of 13 PD patients and 15 controls, we limited our analysis to CpG sites (n = 110,397; Supplementary Fig. 1). There were 1,131 differentially methylated cytosines affecting 341 ALP genes in neurons of PD patients relative to those of controls (3.3 differentially methylated sites per affected ALP gene with 13% average methylation change; q < 0.05, robust linear regression; Fig. 2a; Supplementary Data 6). This cohort replicated the significant hypermethylation of ALP genes in PD neurons (OR = 1.32, p = 5.08 × 10⁻⁶; Fisher’s exact test; Fig. 2b, PFCII). There was also a robust overlap between differentially methylated ALP genes in this cohort of prefrontal cortex neurons and the appendix of PD patients (OR = 4.21, p = 2.33 × 10⁻¹², Fisher’s exact test). Overall, the epigenetic misregulation of the ALP in the PD appendix is recapitulated in the PD brain.

To further investigate the extent to which epigenetic alterations in the PD brain are similar to those in the PD appendix, we investigated different types of genomic elements. We determined whether DNA methylation changes within genomic elements were consistent between the PD brain and PD appendix. In PD patients, DNA methylation differences found in the appendix, prefrontal cortex neurons, and the olfactory bulb were largely concordant across genomic elements, especially within introns and intergenic regions (p < 0.001, Fisher’s exact test; Fig. 2c, Fig. S19). Regions most distal to CpG islands (referred to as “open sea”) also exhibited concordant epigenetic changes in the PD appendix and brain (p < 0.001, Fisher’s exact test; Fig. 2c). Next, we identified active enhancers, poised enhancers, and active promoters that had similar genomic coordinates (±1 kb) in the human brain and appendix (based on PsychEncode data of prefrontal cortex neurons (n = 9 individuals) and the ChIP-seq data in the appendix (n = 3 individuals) described above). We found that the PD appendix and brain had a strong concordant epigenetic dysregulation of active and poised enhancers and active promoters (p < 0.05, Fisher’s exact test; Fig. 2c). In sum, our analyses of DNA methylation demonstrate that the PD appendix and brain show a common epigenetic dysregulation of the ALP that is shared across several types of genomic elements.

We compared the differentially methylated sites at ALP genes identified in the PD prefrontal cortex neurons to those identified in a genome-wide analysis.33 The genome-wide dataset used profiled DNA methylation at all brain enhancers and promoters, examining 904,511 methylated cytosine sites in prefrontal cortex neurons of 57 PD patients and 48 controls. We found that there was a significant overlap of the top loci identified in our ALP dataset with those of the genome-wide dataset (OR = 4.49, p = 1.23 × 10⁻⁶; top 5000 loci examined in each dataset). Thus, comparison with a genome-wide analysis supports an epigenetic disruption of ALP gene elements in PD brain neurons.

ALP genes and proteins disrupted in the PD appendix and brain. We determined specific ALP genes that were the most consistently epigenetically disrupted across the PD appendix and brain. The ALP genes were ranked based on their enrichment for significant DNA methylation changes in the PD appendix, olfactory bulb, and prefrontal cortex neurons, relative to controls. ALP genes exhibiting the strongest epigenetic misregulation across PD tissues were then determined using the cumulative

ARTICLE
The top 40 genes included TLR9, GPNMB, PTEN-induced kinase 1 (PINK1), a well-established familial PD gene, Unc-51 like autophagy activating kinase 1 (ULK1), a mediator of autophagy, and sphingosine kinase 1 (SPHK1), nicotinamide phosphoribosyltransferase (NAMPT), and other genes identified in PD GWAS.
and sirtuin 1 (SIRT1), which impact neurodegeneration and aging processes\textsuperscript{57,58}.

To further investigate the functional consequences of epigenetic dysregulation of the ALP, we performed an unbiased, quantitative proteome analysis of the appendix and brain of PD patients and controls (\(n = 3\) PD and 3 controls per tissue; Supplementary Fig. 1). Overall, 1,341 and 1,743 proteins were quantified in the appendix and prefrontal cortex, respectively (Supplementary Data 8 and 9). Protein abundance changes in the PD appendix and brain were significantly correlated (\(r = 0.26, p < 2.2 \times 10^{-16}\); Pearson correlation). Among the altered proteins were 34 ALP proteins encoded by DNA with an epigenetic dysregulation in the PD appendix (Fig. 3; Supplementary Table 1). These ALP proteins showed a marked concordance in fold change in the PD appendix and prefrontal cortex (\(r = 0.60, p = 0.008\); Pearson correlation), signifying that the PD appendix and brain exhibit similar abnormalities in ALP protein levels. The appendix of PD patients had increased \(\alpha\)-syn protein levels (SNCA), along with decreases of GPNMB, NAMPT, vacuolar protein sorting 35 ortholog (VPS35) and heat shock 7 kDa protein 8 (HSPA8/HSC70), which are all linked to PD risk and affect neuronal survival\textsuperscript{33,35,39–62}. Consistently, several of these proteins had abnormal levels in the PD prefrontal cortex (Fig. 3), including an upregulation of \(\alpha\)-syn (SNCA) and a downregulation of NAMPT, HSPA8, and VPS35 (Supplementary Table 1). Overall, we found that the majority of ALP proteins altered in the PD appendix and prefrontal cortex are also epigenetically altered in their respective tissues (76%, 70%, 85.7% of ALP proteins altered in the PD appendix, prefrontal cortex, or both tissues, respectively, were epigenetically altered). Consequently, there is concordance between the epigenetic and proteome-wide analysis, which together point to a prominent decrease in ALP function and an overabundance of \(\alpha\)-syn in the PD appendix and brain.

In addition, we performed a replication study using a tandem mass tag (TMT) quantitative proteomic analysis to further validate our findings in a lysosome-enriched fraction of appendix tissue (\(n = 5\) control, 5 PD). We identified 2084 proteins including 132 (27%) of the proteins encoded by ALP genes interrogated in this study (Supplementary data 10). We found 175 differentially abundant proteins (FDR \(q < 0.05\), robust linear regression), including 7 ALP proteins encoded by genes that were also epigenetically dysregulated in the human appendix. The overlap of differentially abundant proteins identified in both datasets was higher than expected by chance (\(OR = 1.88, p = 0.04\); Fisher’s exact test), and the proteins identified as differentially abundant in label-free approach had a concordant fold change in the replication dataset (\(r = 0.40, p = 5.99 \times 10^{-25}\); weighted Pearson correlation). Upregulation of SNCA and downregulation of NAMPT, HSPA8, GPNMB and VPS35 was confirmed by fold change estimates in the replicate data. Overall, this analysis confirms the validity of our previous findings.

**Epigenetic age effects indicate disrupted ALP in the PD appendix and brain.** Advanced age is universally considered the greatest risk factor for PD. Why aging exerts such strong risk for PD is not well understood, particularly at a mechanistic level. We investigated the epigenetic age dynamics of the ALP in the healthy human appendix, and determined its relevance to ALP changes occurring in PD. For this analysis, we examined DNA methylation at the 521 ALP genes in 51 healthy (ages 18–92) and 24 PD (ages 62–91) appendix samples and profiled a total of 181,151 CpG sites (Supplementary Fig. 1). As a comparison, we also examined age-related changes in DNA methylation in two brain sample datasets. In prefrontal cortex neurons of 42 control and 52 PD individuals, ages 55–93, we profiled a total 130,733 CpG and 696,665 Cph sites. In olfactory bulb tissue of 14 control and 9 PD individuals, ages 53–92 we profiled a total of 143,553 CpG sites.

In the healthy appendix, there were 285 cytosine sites at 170 ALP genes showing chronological age-related changes in DNA methylation (1.7 differentially methylated sites per affected ALP gene with 0.44% average methylation change per year; \(q < 0.05\), robust linear regression after adjusting for sex, postmortem interval, batch, and other sources of variation by surrogate variables factor analysis; Supplementary Data 11). Though DNA methylation in the aging appendix did not show an overall directional shift at ALP genes (Fig. 4a), there was a prominent hypermethylation of poised enhancers, promoters, and CpG islands and shores with age (\(q < 0.05\), Fisher’s exact test; Supplementary Fig. 7). In prefrontal cortex neurons of controls 304 sites affecting 200 ALP genes changed methylation with age (1.5 differentially methylated sites per affected ALP gene with 0.42% average methylation change per year; \(q < 0.05\), robust linear regression adjusting for sex, postmortem interval, and neuron subtype proportion; Supplementary Data 12). ALP genes in prefrontal cortex neurons largely became hypermethylated with increasing age (OR = 1.65, \(p = 2.55 \times 10^{-5}\); Fisher’s exact test). In olfactory bulb controls there were 853 sites epigenetically changing by age affecting 325 ALP genes (2.6 differentially methylated sites per affected ALP gene with 0.75% average methylation change per year; \(q < 0.05\), robust linear regression adjusting for sex and postmortem interval; Supplementary Data 13). No dominant
The direction of methylation change could be established (OR = 1.06, p = 0.41; Fisher’s exact test).

ALP pathway analysis revealed an overrepresentation of age-related hypermethylation of cytosines among selective autophagy genes in both the appendix and prefrontal cortex neurons, and among macroautophagy genes in the prefrontal cortex (OR = 2.42, p = 0.02; OR = 1.39, p = 0.10 in appendix and OR = 2.06, p = 0.04; OR = 1.42, p = 0.04 in prefrontal cortex neurons, for selective autophagy and macroautophagy, respectively, Fisher’s exact test; Fig. 4b; Supplementary Fig. 8). There was also a strong correlation in the enrichment of all tested pathways between appendix and prefrontal cortex neurons (r = 0.97, p = 0.006, Pearson’s correlation). Together, this suggests that the machinery for degrading aggregated proteins and invading pathogens may be compromised in the appendix and brain with advanced age.

We determined the ALP genes most epigenetically affected by age in the healthy appendix and brain. We ranked ALP genes according to their enrichment in significant DNA methylation changes with chronological age in the appendix and prefrontal cortex, and then consolidated the rankings (using the robust rank aggregation algorithm, as above; Fig. 4c; Supplementary Data 14). The top genes exhibiting convergent DNA methylation abnormalities in the appendix and brain included TANK-binding kinase 1 (TBK1), which plays a key role in initiating selective autophagy; engrailed homeobox 1 (EN1) and LIM homeobox transcription factor 1 beta (LMX1B), which are neuroprotective and affect the functioning of dopamine neurons; calcium-
binding and coiled-coil domain-containing protein 2 (CALCO2), which has been implicated as a key regulator of inflammation in Crohn’s disease74; and auxilin (DNAJC6), mutations of which are associated with early-onset PD69 (Fig. 4c). Hence, the ALP genes most affected by age in the human appendix and cortical neurons are related to selective autophagy, inflammation, and physiological neuronal activity and survival.

We then investigated whether the ALP genes that exhibit age-related changes in healthy controls also differ between PD cases and controls. ALP genes affected by significant age-related DNA methylation changes observed in the control group were compared to the ALP genes affected by significant DNA methylation differences between control and PD patients, examining the appendix and prefrontal cortex neurons separately. We found a significant overlap of age and PD affected ALP genes in the appendix and prefrontal cortex neurons (OR = 3.19, \( p < 2 \times 10^{-16} \); and OR = 2.31, \( p = 0.004 \), respectively, Fisher’s exact test; Fig. 4d). Absolute cytosine methylation age effect rates were significantly positively correlated to absolute methylation changes manifesting in PD, for the appendix, olfactory bulb, and prefrontal cortex neurons (\( r > 0.70, p < 10^{-15} \); Pearson correlation; Supplementary Fig. 9). Hence, the ALP genes that are altered with age are also vulnerable to PD disease processes.

Next, we compared magnitudes of epigenetic age effects among ALP genes in PD patients to that in healthy controls. In the appendix of PD samples there were 561 cytosines changing with age and involving 251 ALP genes. In prefrontal cortex neurons of PD samples there were 77 cytosines changing with age and involving 70 ALP genes. For each ALP gene, we computed the mean magnitude of the age effect weighted by the corresponding \( \beta \) value of each cytosine pertaining to that gene and set the rate to zero if there were no cytosines significantly changing with age (Fig. 4e). In the appendix, we found 118 ALP genes changing with age among both healthy control and PD samples, more than expected by chance (OR = 3.43, \( p < 2.2 \times 10^{-16} \); Fisher’s exact test), and among them there was an agreement of age effect direction (OR = 2.21, \( p = 0.05 \); Fisher’s exact test). The absolute age effect magnitudes of ALP genes were higher in PD than in control samples (\( p = 1.58 \times 10^{-15} \); paired \( t \)-test), suggesting accelerated methylation change with age. In prefrontal cortex neurons, 35 ALP genes were affected with age in both healthy control and PD samples (OR = 1.58, \( p = 0.09 \); Fisher’s exact test); there was no significant agreement of age effect direction nor magnitude (OR = 0.31, \( p = 0.55 \) and \( p = 0.35 \); Fisher’s exact test and paired \( t \)-test, respectively).

To ascertain that our findings are not influenced by the wide age range of appendix controls, we repeated the same analysis using only appendix samples older than 62 years. We confirmed hypermethylation of promoters and again found absolute age effects to be stronger among PD samples (Supplementary Data 20, Supplementary Fig. 18). Taken together, this suggests that in the appendix and prefrontal cortex neurons of PD patients (OR = 3.81, \( p = 4.79 \times 10^{-12} \); paired \( t \)-test, respectively, Fisher’s exact test; Supplementary Fig. 12a, b). However, DNA methylation changes mediated by DSS colitis were greatly exacerbated in the A30P α-syn mice relative to wild-type mice (OR = 1.70, \( p = 7.48 \times 10^{-34} \); Fisher’s exact test). The A30P α-syn mutation alone did not induce significant ALP hypomethylation (Supplementary Fig. 12c). These results suggest that α-syn overexpression strongly sensitizes mice to an intestinal inflammatory insult.

We observed that DSS colitis resulted in the epigenetic disruption of numerous ALP genes associated with PD risk in GWAS (Supplementary Fig. 12a and Supplementary Fig. 12b). Notably, we observed significant hypomethylation of the Snca and Gpmmb genes in the A30P mice given DSS, but not in the wild-type mice given DSS (\( q < 0.05 \), robust linear regression; Supplementary Fig. 12a and Supplementary Fig. 12b); these genes were both epigenetically perturbed in the PD appendix (Fig. 1a).

We then sought to determine whether α-syn aggregation in enteric neurons was a key contributor to epigenetic dysregulation of the ALP induced by intestinal inflammation. In this experiment, we injected into the cecal patch of wild-type C57BL/6 mice a recombinant adeno-associated virus (rAAV) vector that overexpressed either human α-syn or GFP as control74 (Fig. 5a) using direct subserosal delivery to the ENS. This targeted approach results in transduction of neurons per se, with no off-target transduction of support cells such as muscle or glia74. At one month post-injection, there was an abundance of aggregated α-syn positive for phospho-Ser129 in enteric plexuses of the mouse cecal patch (Supplementary Fig. 13). No phospho-Ser129 immunoreactivity was observed in mice treated with the control vector. We measured the effects of α-syn aggregation on DNA methylation changes at the same 571 ALP genes as above, profiling a total of 236,363 cytosine sites in the mouse cecal patch.
Fig. 5 ALP changes in DNA methylation in response to experimental gut inflammation and α-syn aggregation. DNA methylation was fine-mapped in the cecal patch of mice exposed to chronic DSS colitis, examining both wild-type mice and a mouse model of synucleinopathy, A30P α-syn mice (n = 40 mice: 9 A30P/DSS colitis, 10 A30P/Water, 10 WT/DSS colitis, 11 WT/Water). DNA methylation changes in response to α-syn aggregation were examined using a rAAV-mediated α-syn overexpression mouse model (n = 5 control vector and 5 α-syn overexpression vector in wild-type mice). a Schema of experimental design for the gut inflammation (left panel) and vector-mediated α-syn aggregation (right panel) studies. b Comparison of ALP changes induced by rAAV vector-mediated α-syn aggregation to those mediated by gut inflammation in wild-type and A30P α-syn mice. ALP gene enrichment in differentially methylated cytosines was determined. Plot shows concordance of epigenetic changes at ALP genes between rAAV-mediated α-syn aggregation mice and the wild-type and A30P α-syn mice in the DSS colitis study. c Comparison of ALP changes occurring in the PD appendix to those mediated by α-syn aggregation or gut inflammation. Concordance of epigenetic changes at ALP genes between PD appendix study and mouse studies. *p < 0.05, **p < 0.01, ***p < 0.001 Kendall's rank correlation coefficient, two-sided test. d Overlap of hyper- and hypo-methylated genes differentially methylated in PD appendix, rAAV α-syn and A30P water treated mice with synucleinopathy and A30P and wild-type mice with DSS colitis. Genes in each overlapping domain were tested for enrichment by ALP pathway genes using two-sided Fisher’s exact test. Actual p values are reported in Supplementary Data 21.

(Supplementary Fig. 1). We found 896 differentially methylated cytosines affecting 365 ALP genes in response to α-syn aggregation (2.5 differentially methylated sites per affected ALP gene with 10.85% average methylation change; q < 0.05, robust linear regression; Supplementary Fig. 14; Supplementary Data 16). We next determined whether similar ALP genes were epigenetically altered in mice with rAAV-mediated α-syn overexpression and mice exposed to DSS-mediated intestinal inflammation. We observed that α-syn overexpression and aggregation by the rAAV vector paralleled the effects of A30P α-syn overexpression on the ALP epigenome in the mouse cecal patch (r = 0.20, p = 3.65 × 10^{-6}, Kendall’s rank correlation coefficient; 246 overlapping differentially methylated genes; Fig. 5b). Interestingly, we found a significant positive correlation between the epigenetically altered ALP genes in response to inflammation and those altered in response to α-syn aggregation by rAAV-mediated overexpression (wild-type and A30P α-syn mice: r = 0.11, p = 3.25 × 10^{-3} and r = 0.13, p = 4.76 × 10^{-4}, Kendall’s rank correlation coefficient; 298 and 303 overlapping differentially methylated genes, respectively; Fig. 5b). Thus, ALP genes epigenetically altered by α-syn aggregation are also affected by intestinal inflammation.

We determined whether ALP genes altered by α-syn aggregation and gut inflammation in the cecal patch are consistent with those differentially affected in the appendix of PD patients. We found that differentially methylated ALP genes were concordant between the A30P α-syn overexpression mouse model and the PD appendix (r = 0.10, p = 0.04, Kendall’s rank correlation coefficient; Fig. 5c). Of the 326 differentially methylated ALP genes in the PD appendix, there were 176 gene homologs that were differentially methylated in the mice overexpressing A30P α-syn relative to wild-type mice. Further, pathway analysis revealed that α-syn overexpression in the A30P mouse model recapitulated the abnormalities in lysosome function in the PD appendix and affected autophagy (OR = 2.63, p = 0.001 and OR = 1.85, p = 0.04, respectively, Fisher’s exact test; Supplementary Fig. 15). In addition, we examined the overlap of the genes exhibiting predominant hypermethylation or hypomethylation in the PD appendix, in mice with synucleinopathy, and in mice in response to DSS colitis (Fig. 5d; Supplementary Data 17). We performed a pathway analysis for overlapping genes, and again found that the PD appendix and mice with synucleinopathy shared a hypermethylation of lysosomal genes (OR = 1.9, p = 0.03; Fisher’s exact test). Meanwhile, there was a hypomethylation of genes involved in autophagy that overlapped between PD appendix, mice with synucleinopathy and following DSS colitis (OR = 2.16, p = 0.01; Fisher’s exact test). Therefore, even though there is a predominant hypermethylation of lysosomal genes in the PD appendix and induced by synucleinopathy, there are autophagy genes exhibiting hypomethylation that are in common between the PD appendix, mice with synucleinopathy, and mice exposed to gut inflammation.

**Discussion**
Our highly detailed deep-sequencing maps of 521 ALP genes in the healthy and PD human appendix and in neurons of the prefrontal cortex and olfactory bulb serve as a rich resource for...
exploring the dysregulation of ALP genes in PD. First, we demonstrate a pronounced hypermethylation of ALP genes in the PD appendix. Specifically, genes implicated in lysosomal function exhibit significant downregulation. Second, we confirm that the pattern of hypermethylation in the PD appendix is recapitulated in the PD brain, in the olfactory bulb and in prefrontal cortex neurons, with a significant overlap of the specific ALP genes affected. Third, we observe a gradual hypermethylation of selective autophagy genes with age in the healthy appendix and brain, as well as a hypermethylation of macroautophagy genes in the brain. Fourth, we demonstrate that the normal epigenetic age effects of ALP genes are disrupted in PD. Fifth, and finally, we show that overexpression of α-syn sensitizes to the effects of gut inflammation in vivo. Together, our translational study demonstrates that the ALP, and specifically the lysosomal pathway, is epigenetically disrupted in the PD appendix, making it a potential culprit for PD initiation and progression (Fig. 6).

We found a widespread epigenetic silencing of the ALP in the PD appendix and brain, particularly for lysosomal genes, with concomitant transcriptional downregulation of lysosomal pathways. Our human studies do not discern whether epigenetic changes at ALP genes are causal to PD or a consequence of PD pathophysiology, though we used a computational approach (SVA) and follow-up studies in mice in an effort to address potential confounding factors (i.e., non-shared environment, cell-type heterogeneity). Moreover, an epigenetic inactivation of the lysosomal system is in line with PD GWAS identifying a role for lysosomal genes in PD^{33}. It is also consistent with studies identifying considerable genetic risk overlap between PD and lysosomal storage diseases, such as Gaucher’s disease^{68} and Niemann-Pick disease^{76}. Lending further evidence to the centrality of lysosomal function to PD, human postmortem studies indicate abnormalities in lysosomal proteins in idiopathic PD^{7,27}. Transcriptomic studies of the PD brain and of induced dopaminergic neurons from PD patients support lysosomal dysregulation in this disease^{25,78-80}. A recent study also demonstrated an abundance of lysosomal markers and vesicles in PD Lewy pathology^{81}. The genetic and/or chemical manipulation of lysosomes in model systems contribute to the accumulation of α-syn^{82}, while aggregated α-syn itself appears to impede lysosomal function^{83,84}. There is also evidence that compromised lysosomal function, leading to a decrease in autophagic flux, contributes to the secretion and cell-to-cell transmission of α-syn aggregates^{85,86}, which may occur via exosomes^{22}, endocytosis^{36}, or tunneling nanotubes^{87}. Here, we present a new line of evidence suggesting that epigenetic misregulation of the ALP, particularly of lysosomes, is responsible for its dysfunction in the PD gut and brain.

Epigenetically induced dysfunction of the ALP in the PD appendix may contribute to the accumulation of aggregated α-syn in the gut and brain. In the PD appendix, widespread epigenetic inactivation of the ALP signifies that this tissue site exhibits molecular changes capable of promoting synucleinopathy; however, this study does not delineate whether the ALP dysregulation in the PD appendix preceded that of the PD brain. Nonetheless, imaging studies of prodromal PD patients support that pathology can occur in the gut prior to the brain^{11}. Aggregated α-syn has also been detected in enteric neurons of individuals in the prodromal stage of PD^{7,11}—in some cases as early as 20 years prior to the onset of motor symptoms^{3}. Studies using animal models have demonstrated that α-syn pathology is capable of propagating from the gut to the brain via the vagus nerve^{3,89}, though there is also evidence for bidirectional transfer of aggregated α-syn between the gut and brain^{88,89}. Transfer of α-syn pathology from the enteric nervous system to the CNS has been observed in a variety of α-syn models^{72,90,91}. While it is unclear, what triggers the enteric α-syn pathology and its propagation to the brain, recent studies in α-syn transgenic mice demonstrate that α-syn pathology develops in the brain 18 months post an experimental form of colitis but not at 6 months post colitis which was accompanied by dopaminergic neuronal loss in the substantia nigra^{92}. In humans, colitis and the prodromal appearance of enteric α-syn pathology have also been implicated as a risk factor for PD as well as several genes related to immune function^{92}. We previously reported that there can be an abundance of aggregated α-syn in both the healthy and PD appendix, although α-syn levels are up to three times greater in the PD appendix^{12}. In combination with epigenetic perturbation of lysosomal function, hypomethylation of the α-syn gene in the PD appendix may propel α-syn pathology. Indeed, studies in the brain have found that endogenous α-syn levels influence the spread of synucleinopathy^{93}. Thus, epigenetic changes in the PD appendix are consistent with an increased production and impaired clearance of α-syn pathology.

In patients in which PD has fully emerged, epigenetic changes at ALP genes in the PD appendix are similar to those occurring in
the PD brain. Our proteomic analysis also identified consistently increased levels of α-syn protein (SNCA) and decreased levels of NAMPT, HSPA8, and VPS35 in both the PD appendix and brain. Similarities across the PD gut and brain signify that the epigenetically dysregulated genes that enable the development, progression, and transport of α-syn pathology in the appendix could also facilitate the propagation of pathology within the brain. The appendiceal orifice is routinely identified during a total colonic examination and can be biopsied\textsuperscript{84}, and as such, is more accessible than the brain. Our findings suggest that epigenetic changes in the ALP in the appendix may serve as a proxy for ALP status in the brain, though this would require further investigation across disease stages.

Typical epigenetic age effects on the ALP appear to be disrupted in PD. In the healthy appendix and prefrontal cortex, we found that the cytosines hypermethylated with age were overrepresented among genes in the selective autophagy pathway. In the brain, hypermethylated cytosines were also overrepresented at macroautophagy genes. Selective autophagy, which involves the targeting of specific cargos by ubiquitin tagging, includes the clearance of intracellular pathogens, also referred to as xenophagy\textsuperscript{95}. The accumulation of suppressive epigenetic marks affecting selective autophagy with age suggests that the brain may be more susceptible to infection in advanced age. Chaperone-mediated autophagy (CMA) and macroautophagy are thought to be key pathways through which physiological α-syn and aggregated α-syn, respectively, are cleared from the cell\textsuperscript{4,83}. The hypermethylation of macroautophagy genes in the healthy aging brain may consequently render older individuals more vulnerable to the accumulation of α-syn aggregates. Though advanced age places individuals at greater risk for PD, the ALP in PD patients fails to exhibit normative epigenetic changes with age. It may be the case that, in PD, various ALP pathways (e.g., macroautophagy, selective autophagy) do not undergo the same extent of hypermethylation as in healthy aging, in a futile attempt to compensate for the decrease in autophagic flux induced by lysosomal dysfunction.

For this study we selected prefrontal cortex neurons because of their relevance in later stages of PD and because prefrontal cortex neurons still exist in the analyzed early stage (Braak stage 3–4) postmortem PD brain. In contrast, substantia nigra neurons have largely degenerated and therefore are insufficiently present or are too advanced in the degenerative process for isolation\textsuperscript{96}. On a technical level, neuronal nuclei isolation has been fully optimized for the prefrontal cortex, and the prefrontal cortex yields sufficient numbers of neurons for DNA methylation analysis\textsuperscript{52,97}. Epigenetic (DNA methylation) changes in prefrontal cortex neurons can occur early in neurodegenerative diseases\textsuperscript{52,97,98}. Hence, for our study of molecular changes in the early PD brain neurons, the prefrontal cortex offers a disease-relevant and available source of neurons, in combination with technical feasibility. Our study of normal age-related methylation changes in the appendix is somewhat limited by potential confounding factors in the individuals from which it was obtained. Although the control appendix tissue was confirmed to be histologically normal, the patient diagnosis of intestinal cancer leading to incidental appendix removal may have impacted some of the methylation changes observed, particularly those related to inflammatory pathways. Nevertheless, we verified that age-related genes observed in these appendices overlap with those seen in prefrontal cortex neurons from other control individuals, suggesting that the control appendix samples exhibit healthy aging, at least in part. Follow-up studies in a second cohort of the normal appendix would further validate our results and strengthen our understanding of normal age-related changes of methylation in the appendix.

The causative factors of the epigenetic dysregulation of the ALP in PD remain unclear, although there is evidence for a bidirectional relationship between α-syn and the ALP\textsuperscript{19,21}. Decreased autophagic flux results in an accumulation of α-syn\textsuperscript{9,92,93}, and misfolded α-syn itself appears to play an active role in suppressing the ALP\textsuperscript{93,94}. In this way, genetic and/or epigenetic defects in the ALP leading to α-syn accumulation could lead to further (epigenetic) dysregulation of the ALP. This is supported by our finding that the same ALP genes are disrupted in a mouse model with α-syn overexpression as in the human PD appendix. In addition to the joint contribution of genetic risk factors\textsuperscript{22,25} and α-syn accumulation triggering epigenetic disruption of the ALP, environmental agents\textsuperscript{99} and abnormal shifts in the microbiome\textsuperscript{100} may play a role, especially because they can impact gut inflammation.

There is a robust interplay between inflammation and the ALP\textsuperscript{101}. Autophagy is involved in the induction and suppression of inflammation\textsuperscript{101,102}. It regulates the development, homeostasis, and survival of inflammatory cells and affects the transcription, processing, and secretion of cytokines\textsuperscript{103}. Loss of autophagy has proinflammatory consequences, and in the gut, ALP suppression exacerbates the inflammatory effects of DSS colitis\textsuperscript{102,103}. In our study, gut inflammation mediated by DSS largely induced a hypomethylation of the ALP. This is consistent with evidence that activation of autophagy is important for resolving inflammation\textsuperscript{101,102}. Furthermore, DSS colitis effects on the ALP were amplified by synucleinopathy. Synucleinopathy in mice induced a hypermethylation of lysosomal genes which was consistent with that observed in PD. Thus, the exaggerated response to an inflammatory event may be an increased activation of autophagy in an attempt to overcome deficient lysosomal function mediated by α-syn accumulation. Indeed, we find that autophagy genes exhibiting hypomethylation are in common between the PD appendix and mice models of synucleinopathy and gut inflammation, while lysosomal genes are hypermethylated in the PD appendix and by synucleinopathy. Excessive or prolonged autophagy stimulation is detrimental as it can lead to cell death, including in the GI tract (known as autophagic cell death and autosis)\textsuperscript{104–107}. Thus, our study suggests that epigenetically mediated ALP abnormalities in the PD appendix may, in part, be due to an accumulation of α-syn. Given the evidence supporting that inflammation (including in the GI tract) plays a key role in PD pathogenesis\textsuperscript{69,70}, it is possible that normative ALP activation needed to resolve inflammation is incapacitated in PD.

Recent studies have also provided evidence for a link between gut inflammation and PD\textsuperscript{108}, including a higher likelihood of developing PD among individuals with inflammatory bowel disorders (IBD)\textsuperscript{69,70}. Several of the ALP genes we found consistently epigenetically suppressed across the PD gut and brain have direct roles in inhibiting inflammation under physiologically normal conditions\textsuperscript{51,67,109–115}. In addition, two of the top dysregulated ALP genes, TIAL1 and CALCCOC2, have been implicated as key factors in ulcerative colitis- and Crohn’s disease-related inflammation, respectively\textsuperscript{67,112}. There is also evidence for the involvement of α-syn in rallying an immune response in the GI tract in response to infection\textsuperscript{116} and that α-syn is upregulated in response to viral\textsuperscript{117} and bacterial infections\textsuperscript{118}. Inflammation, induced by DSS, activated the ALP in both wild-type and A30P α-syn overexpressing mice, with a significantly exaggerated response in the A30P α-syn mice. If α-syn pathology does originate in the gut for some individuals, then the heightened response in the A30P α-syn mice suggests that α-syn-dependent changes in the ALP may sensitize individuals to an increased risk of developing both PD and IBD. Hence, abnormalities in gut α-syn expression and the effects of α-syn on the ALP may contribute to the heightened co-occurrence of IBD and PD\textsuperscript{69,70}. 
In sum, the ALP faces widespread epigenetic dysregulation in the PD appendix and brain. Our findings add to evidence suggesting the potential for the gut as an initiation site for idiopathic PD. Further study of the ALP abnormalities we have identified could provide key insights into gut-based methods for tracking disease progression and for preventative strategies.

Methods

Within each dataset all measurements were taken from distinct samples. All data analyses were performed using R programming language (v. 3.6.1), unless explicitly specified otherwise.

Human tissue samples. Postmortem appendix tissue from PD patients and controls was obtained from the Oregon Brain Bank. In our age effect analysis, we included surgically-isolated, histologically normal appendix tissue from control (non-PD) individuals obtained from the Spectrum Health Universal Biorepository and Cooperative Human Tissue Network (CHTN). Appendix surgical samples were from individuals undergoing a right hemicolectomy for intestinal cancer not involving the appendix (appendix incidentally removed and histologically confirmed to be normal). Prefrontal cortex tissue was obtained from the NIH NeuroBioBank, Parkinson’s UK Brain Bank, Michigan Brain Bank (primary cohort), or the Oregon Brain Bank (replication cohort). Olfactory bulb tissue was obtained from the Oregon Brain Bank. For the study samples, we had information on demographics (age, sex), tissue quality (postmortem/surgical interval), and pathological staging (Supplementary Data 15). Appendix, prefrontal cortex, and olfactory bulb postmortem tissue from PD patients have evident brain Lewy pathology (PD Braak stages III-VI), whereas control individuals have no Lewy pathology (PD Braak stages 0-1). Sample information is detailed in Supplementary Data 18. All fresh tissues were snap-frozen and stored at −80°C until time of processing. Neuronal nuclei from prefrontal cortex were isolated using an antibody (NeuN) and flow cytometry—based approach. First, fresh frozen tissue was homogenized on ice in PBSTA buffer (0.3 M sucrose, 1 × Dulbecco’s PBS (Gibco), 3 mM MgCl2) for three extracts of 5 s (BioTissue Tearer, on lowest setting), followed by incubation for 15 min with 0.2% Triton X-100. Next, the tissue homogenate was further homogenized with eight strokes in a dounce (Kimble). To remove debris, the homogenate was filtered through Miracloth (Calbiochem) onto a sucrose cushion (1.4 M sucrose, 1 × Dulbecco’s PBS (Gibco), 0.1% Triton X-100, 3 mM MgCl2) and maintained at 3000 × g for 10 min at 4°C. The supernatant was removed by centrifugation at 80°C until DNA isolation. The study complied with all relevant ethical regulations for work with human participants, informed consent was obtained and the protocol was ethically approved by the institutional review board at the Van Andel Research Institute (IRB #15025).

DNA methylation fine-mapping with bisulfite padlock probe sequencing. We comprehensively profiled DNA methylation at all genes involved in the ALP, as reported on the Human Autophagy Database (https://autophagy.lu)9 and Human Lysosome Gene Database (http://lysosome.unipg.it).40. To our panel, we also added genes from the PDGene website (http://www.pdgene.org/) because of the involvement of PD risk genes in the ALP. DNA methylation was fine-mapped at 521 ALP genes in the replication cohort of 13 PD and 15 control prefrontal cortex neurons, 4) the replication cohort of PD and control prefrontal cortex neurons, 5) PD and control olfactory bulb, 6) the gut inflammation mouse model, and 7) the rAAV-a-syn overexpression mouse model (Supplementary Fig. 1). Preprocessing was done jointly for the human appendices (n = 77 unique samples, 16 technical replicates), as well as for the mouse datasets (n = 50 unique samples, 7 technical replicates). Brain datasets were each preprocessed independently: prefrontal cortex neurons (98 unique samples, 4 technical replicates in primary cohort; 31 unique samples in replication cohort) and olfactory bulb (24 unique samples, 2 technical replicates).

We confirmed that technical reproducibility exceeded biological variability in the human and mouse datasets. In the prefrontal cortex neuron datasets, there was one sample in each dataset excluded because of a low inter-sample cytosine methylation correlation (Pearson correlation coefficient r ≤ 0.9). For technical replicates, methylation values and counts were averaged across replicates. Sites with less than 70% of samples containing methylation calls as well as sites with all samples having a methylation call of 0 were removed from further analysis. Sites overlapping common SNPs in the population (minor allele frequency ≥ 0.05), as identified by the 1000 Genomes Project (phase 3 v5a 20130502 release for chr1–22, and 20130502 for chrX, Y and non-canonical populations and European populations) were also removed from further analysis.

We next explored the data using principal component analysis (PCA) of beta values defined as B = M/(M + U). PCA of all datasets was computed and sample projection onto the first two principal components was plotted, which served to identify outlier samples. Sample clustering frequently separated the ALP and control datasets. Sites with stable DNA methylation calls (0%, 100%, and/or missing) in 50% or more of the samples were excluded from further analysis. Normalized B values for appendix datasets were log_{10} transformed and log_{10} centered, as the distribution of B values were significantly skewed. Sites with stable DNA methylation calls (0%, 100%, and/or missing) in 50% or more of the samples were excluded from further analysis.

After data processing we had the following datasets for downstream statistical analysis: (1) 182,024 CpGs in 24 PD and 19 control appendix samples, (2) 181,151 CpGs in 24 PD and 51 healthy appendix, (3) 130,733 CpGs and 696,665 CpHs in the primary cohort of 13 PD and 15 control prefrontal cortex neurons, (4) 110,397 CpGs in the replication cohort of 13 PD and 15 control prefrontal cortex neurons, (5) 143,553 CpGs in the 9 PD and 14 control olfactory bulb, (6) 240,366 CpGs in the gut inflammation model (n = 11 wild-type + water, 10 wild-type + DSS, 10 A30P + water, 9 A30P + DSS, 10 A30P + water, 9 A30P + DSS) in the AAV-a-syn overexpression mouse model (n = 5 rAAV-GFP, 5 rAAV-a-syn). For each dataset, m values were computed from beta values. First, extreme B values were shrunk towards the center B = (B + (B − 1))/0.5, where f is the shrinkage factor set to 1000 for appendix and mice datasets, and, to accommodate C values, C was set to 2000. Next, m values were log_{10} transformed, m = log_{10}(B/(1−B)). Robust linear regression was fitted to each cytosine site with a maximum number of model fitting iterations set to 100 using limma.122. The...
regression models for the human datasets included the following covariates: diagnosis (PD, control), age, sex, postmortem interval, and surrogate variables to correct for other sources of variation. Surrogate variables were selected using SmartVAM, a benchmark approach to control for cell-type heterogeneity and effective removal of other sources of variation. The number of surrogate variables was determined by performing PCA on residuals of the m-value matrix after regression of all known covariates and counting the number of principal components explaining more than 5% of variability. In the prefrontal cortex neuron dataset, we also adjusted for neuronal subtype proportion, which refers to the proportion of glutamatergic to GABA neuronal subtypes, using cell-type deconvolution performed with CIBERSORT via http://cibersort.stanford.edu/. The default protocol was based on that of the NIH Roadmap Epigenomics Project.

Appendix tissue was first cryoground into a fine powder using liquid nitrogen and a mortar and pestle. Frozen appendix tissue powder (~50 mg) for each sample was quickly suspended into 5 ml of ice-cold PBS and 0.5 ml of fresh crosslinker buffer (0.1 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM HEPES pH 8.0, and 11% formamide), and the sample was nanod for 7 min at room temperature. Cross-linking was quenched in 125 mM glycine and rotation for 5 min at room temperature. Samples were then centrifuged for 15 min at 2,000 g and the pellet was washed with 5 ml of ice-cold PBS. Samples were then centrifuged again for 10 min at 2,000 g and the pellet was stored at −80°C until further processing. Each cross-linked tissue sample was then lysed by adding 100 μl of lysis buffer (1% SDS, 50 mM Tris-HCl pH 8.0, 20 mM EDTA, Complete protease inhibitor cocktail (Roche), and 1 mM PMSE), passing the solution through a 26 g needle 10 times, followed by incubation on ice for 10 min. Samples were then placed into 1 ml of ice-cold phenol-chloroform Tris-buffer (1 mM EDTA) and stored at −20°C for 20 min using the E220 ultrasonicator (Covaris), which was operated with a 200–500 bp sheared DNA length. To perform the ChIP, 200 μl of sheared DNA was exposed to 5 μg of anti-histone H3 acetyl K27 antibody (1:40, Abcam #ab4729), anti-histone H3 mono methyl K4 antibody (1:40, Abcam #ab8895), or control IgG (1:40, Cell Signaling). Samples were incubated overnight at 4°C with gentle rotation. Samples were then incubated with Dynabead Protein G beads (Thermo Fisher Scientific) for 10 min at room temperature. DNA-protein complexes on beads were washed 5 times with ice-cold modified RIPA (5 mM HEPES pH 8.0, 1% NP-40, 0.7% sodium deoxycholate, 0.5 M LiCl, Complete protease inhibitor cocktail (Roche), and 1 mM PMSE) and incubated with 150 μl of RIPA and reverse crosslinks, beads were incubated in 120 μl elution buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 1% SDS) at 65°C overnight. For input DNA, 20 μl of sheared chromatin was added to 130 μl elution buffer and now processed in parallel with the ChIP samples. Following overnight incubation, 250 μl of TE was added to each sample with 0.2 mg/ml RNase A (Thermo Fisher Scientific) and incubated at 37°C for 1 h. Then 0.4 mg/ml proteinase K (Thermo Fisher Scientific) was added and incubated at 55°C for 1 h. DNA was then purified with phenol–chloroform extraction and suspended in 10 mM Tris-HCl pH 8.0. Target fold enrichment relative to IgG control (205.0 for HSK27ac, 44.5 for HSK4me1) was measured using qPCR on an ABI StepOne Plus system (primers in Supplementary Data 16).

Libraries for appendix ChIP (HSK27ac, HSK4me1) and input samples were prepared by the Van Andel Genomics Core from 10 ng of total RNA using the KAPA RNA HyperPrep Kit with RiboseErase (v1.16; for PD vs control appendix) or KAPA stranded mRNA-seq kit (v5.17; for aging appendix) (Kapa Biosystems). RNA was sheared to 300–400 bp. Prior to PCR amplification, cDNA fragments were ligated to NEXTflex dual adapters (Bioo Scientific). The quality and quantity of the finished libraries were assessed using a combination of Agilent DNA High Sensitivity chip (Agilent Technologies), QuantFluor dsDNA System (Promega Corp), and the Kapa Illumina Library Quantification qPCR assays (Kapa Biosystems). Individually indexed libraries were pooled, and 100-bp, single-end sequencing was performed on an Illumina NovaSeq6000 sequencer using an S1 100 cycle kit (Illumina Inc.), with all libraries run on a single lane to return an average depth of 57 million reads per library. Base calling was performed using Illumina RTA and output of FCS was demultiplexed and converted to FastQ format with Illumina Bcl2fastq v1.90.

For the RNA-seq analysis, Trim Galore (v0.4.4) was applied to remove low-quality bases and for adapter trimming. STAR (v2.5.3a) was used to index the Ensembl GRCh37 p13 primary assembly genome with the Genome v19 primary assembly annotation. STAR (v2.5.3a) was then used for read alignment to the genome. Expected gene-level counts were obtained after processing of raw RNA-seq reads with RSEM (v1.28). The edgeR package was used to read the counts of all samples and transform them into count per million values (CPM). Only the genes having more than 1 CPM in 80% of samples were retained. Next, transcript weighting factors were loaded from trimmed input data. TPM (transcript per million) was the default output. TPM values were adjusted for the mean-variance relationship. The resulting matrix was used to calculate surrogate values for the vectors perform linear model fitting. The linear regression model approach is commonly used for RNA-seq analysis. For the PD vs control appendix dataset, a robust linear regression model was used to examine the effects of diagnosis, after adjusting for age, sex, postmortem interval, RNA integrity (RIN), and surrogate variables (SmartSVAM vectors). For the analysis of age effects in appendix, a robust linear regression model was used to examine age, diagnosis, and their interaction, after adjusting for sex, postmortem interval, batch, RIN, and surrogate variables (SmartSVAM vectors). The age covariate was used to determine age effects. P-values for each tested contrast were adjusted using Benjamini-Hochberg false discovery rate correction, and genes with FDR q < 0.05 were deemed significant.
cytosines in types of genomic elements in the PD appendix, the Bioconductor annotation package was used to determine the coordinates of 3’UTRs, introns, exons, 3’UTR promoters, 1 to 5 kb upstream regions, intergenic regions, as well as CpG islands, shores, shelves, and open sea. Appendix ChIP-seq peaks were used to define active promoters as well as active and poised enhancers. To determine enrichment of differentially methylated cytosines in genomic elements, the odds of observing a differentially methylated cytosine within an element type was compared to the odds of observing the same associated sites. Gene element enrichment analyses for all, hypermethylated, and hypomethylated cytosines were performed similarly. We also examined the proximity of differentially methylated cytosines in the PD appendix to the transcription start site of ALP genes. Transcription start coordinates of ALP genes targeted in the DNA methylation analysis were obtained using Bioconductor package TxDb.Hsapiens.UCSC.hg19.knownGene. We examined all ALP genes targeted in the DNA methylation analysis, and we also stratified the ALP genes into those belonging to the lysosome pathway and the rest. Every cytosine was assigned a 20 kb-wide bin based on the distance to the transcription start site of the nearest ALP gene. For each bin and gene strata, the odds of observing differentially methylated cytosines in a given bin was compared to the odds of observing differentially methylated cytosines outside of the bin in the same gene strata.

We also determined whether there was a significant overlap in ALP genes between PD appendix and brain datasets. Disrupted ALP genes had at least one differentially methylated site, and we determined the enrichment of overlap of disrupted ALP genes across datasets relative to the remaining genes. To determine the types of genomic elements with DNA methylation changes overlapping between the PD appendix and PD brain datasets, we examined the top 5000 most significant differentially methylated cytosines in each dataset. For each genomic element category, we calculated the odds of observing differentially methylated cytosines in the same genomic element in the PD appendix and PD brain, compared to the odds of having differentially methylated genomic elements in only one of the tissues. In addition, the overlap of differentially methylated active promoters, and active and poised enhancers between PD appendix and PD brain was performed using the Bioconductor Psychencode data (n = 9 individuals, prefrontal cortex neurons)138. Regions belonging to the same category (active or poised enhancer, active promoter) and overlapping within 1 kb were examined.

In the Manhattan plots displaying the ALP gene enrichment analysis for each dataset, PD risk genes identified by STRING-db were plotted. For at least one differentially methylated cytosine are denoted. For any ALP gene the direction of DNA methylation change test the enrichment of up- and down-regulated ALP pathways using Fisher exact test the enrichment of overlap of differentially methylated cytosines and differentially expressed genes. Gene lists pertaining to the gene. Log transformed p value was used as weight putting the most emphasis on the most significant cytosine.

Human pathway analysis. We determined ALP pathways enriched with differentially methylated cytosines and differentially expressed genes. Gene lists belonging to ALP Gene Ontology (GO) pathways were obtained from http://geneontology.org (retrieved on 2019-07-01) with GO IDs: GO:0006914 for Autophagy, GO:0006184 for Chaperone-mediated autophagy, GO:0005764 for Lysosomes, GO:0016236 for Macroautophagy, and GO:0061912 for Selective Autophagy. For the PD appendix dataset, the Bioconductor Psychencode data (n = 9 individuals, prefrontal cortex neurons)138. Regions belonging to the same category (active or poised enhancer, active promoter) and overlapping within 1 kb were examined.

In the Manhattan plots displaying the ALP gene enrichment analysis for each dataset, PD risk genes identified by STRING-db were plotted. For at least one differentially methylated cytosine are denoted. For any ALP gene the direction of DNA methylation change test the enrichment of overlap of differentially methylated cytosines and differentially expressed genes. Gene lists pertaining to the gene. Log transformed p value was used as weight putting the most emphasis on the most significant cytosine.
The raw mass spectrometry data were searched using PEAKS Studio (Bioinformatics Solutions Inc., Waterloo, ON, Canada, version 10.5) against a combined protein database of RefSeq human entries and common MS contaminants. De novo sequencing of peptides, database search and characterizing specific PTMs were used to analyze the raw data; false discovery rate (FDR) was set to ≤0.05, and [−10log(P)] was calculated accordingly. The search parameters included a maximum of two missed cleavages, carbamidomethylation at cysteine and TMT10plex as fixed modifications with oxidation at methionine as a variable modification. The precursor tolerance was set to 10 ppm and MS/MS tolerance to ≤0.05 Da for both de novo and database searches. Purity correction factors for proteins were determined using loci that were nominally significant in both datasets. We also compared epigenetic age effect patterns of the ALP genes in the healthy and PD appendix and prefrontal cortex. Summarized age effect trend for each gene was computed as weighted mean absolute expression in their host tissues across all cytosines, then epigenetically altered aging p value was used as weight. The age effect trend was set to zero for the ALP genes that did not have a single cytosine significantly affected by age (FDR p < 0.05).

Experimental gut inflammation in wild-type and PD mouse model. We profiled epigenetic changes in the ALP of mice that were exposed to experimental colitis. We examined wild-type mice and a mouse model of synucleinopathy, hemizygous Tg(Thy1-SCNA*30P)18Pjk mice (A30P α-syn)[142]. A30P α-syn mice express human α-syn with the A30P mutation under the neuronal selective Thy1 promoter[42]. A30P α-syn mice have been maintained on a C57BL/6 background for more than 10 generations. Colitis was induced using dextran sodium sulfate (DSS), a widely used model of ulcerative colitis[71–73]. At 3 months of age, wild-type and A30P α-syn mice were exposed to a chronic DSS protocol, consisting of 4 cycles of increasing DSS concentration of 2.5%, to 3.0%, to 3.5%, to 4%. One cycle comprised of 5 days of DSS followed by 2 days of water (DSS: 160110, MP Biologicals, LLC). Non-DSS groups were administered normal drinking water. Mice were then given a 4-week long recovery period during which they received normal drinking water, followed by tissue harvest. Mice were anesthetized with pentobarbital and trans-cardially perfused with PBS before tissue collection. Cecal patch tissue was stored at −80 °C. DNA methylation analysis. A 1-cm part of colon proximal to the cecum was post-fixed 24 h in 4% PFA followed by 30% sucrose in PBS until processing for paraffin embedding. Pathway enrichment analysis. The experiment using rAAV vectors in mice was performed in accordance with the local animal welfare authorities in Canton Basel-Stadt, Basel, Switzerland. The mice were generated and kept in drinking water, followed by tissue harvest. Mice were anesthetized using isoﬂurane and a full laparotomy was performed to expose the cecal patch on the cecum. Each mouse cecal patch region received two 2 µl injections at a titer of 6 × 10^13 vg/ml of rAAV α-syn (n = 10) or control vector (n = 10). Injections were performed with an automated microprop at 1 µl/s. Following the injection, the needle was left in place for an additional 10–20 s to allow the injection pressure to dissipate. All mice administered rAAV-α-syn or control vectors to the cecal patch fully recovered from surgery, consistent with prior studies[141,142]. Following surgery, mice were allowed to recover for 4 weeks. Mice were then killed by exposure to tissue harvest. Digital droplet PCR analysis of rAAV genomes[44] confirmed the successful rAAV injection into the mouse cecal patch (Supplementary Fig. 13C).

We used 5 rAAV-α-syn and 5 control mice for DNA methylation analysis at ALP gene expression and used 5 rAAV-α-syn and 5 control mice for immunohistochemistry analysis. The experiment using rAAV vectors in mice was performed in accordance with the local animal welfare authorities in Canton Basel-Stadt, Basel, Switzerland.

Mice datasets comparisons. We tested whether the A30P α-syn mice have stronger epigenetic responses to DSS than wild-type mice. In this analysis, we compared the fold changes of differentially methylated cytosines in wild-type and/or A30P α-syn mice exposed to DSS. The odds of observing greater fold change in A30P α-syn mice (relative to wild-types) among the differentially methylated sites were compared to that of the non-significant loci. Fisher’s exact test was used to compute the p-value. Next, we examined the concordance of DNA methylation changes in ALP genes between the mouse groups and between the PD appendix and mouse studies. In mice experiments, the enrichment of each ALP gene with significantly differentially methylated cytosines was computed using Fisher’s exact test as described above. Kendall’s rank correlation coefficient, which does not make assumptions about the distribution of resulting odds ratios, was used to evaluate concordance between epigenetically altered ALP genes in the rAAV-α-syn mice and the mouse groups in the DSS study. Similarly, odds ratios of gene enrichment with differentially methylated cytosines were computed for PD appendix dataset, and the odds ratios were compared with those of the homologous genes in the mouse studies. P values were corrected for multiple testing. The significant fold change in the mouse ALP pathways was determined using Fisher’s exact test. Likewise, the genes from the rAAV α-syn study were intersected with the genes of each mouse comparison group in the DSS study, and their enrichment within mouse ALP pathways was tested using Fisher’s exact test. Gene lists pertaining to the mouse ALP pathways were downloaded from Mouse Genome Informatics (website: http://www.informatics.jax.org) using the GO accession numbers matched to the human pathway analysis. ALP genes differentially methylated in appendix were overlapped with those differentially methylated in synucleinopathy or DSS colitis. The genes differentially methylated in either rAAV α-syn mice or between A30P and wild-type mice treated with water were deemed as affected due to synucleinopathy. Similarly, the genes affected by DSS colitis were those that showed difference between DSS and water treatments in either A30P or wild-type mice. As before, the dominant direction of methylation for a gene was determined by majority significantly affected cytosines with ties resolved by weighted mean fold change.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. All sequencing data generated in this study are freely available from the NCBI Gene Expression Omnibus (GEO) database under the accession number GSE135751. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE[143] partner repository with the dataset identifiers PXD015079 and PXD021757.
References

1. Nussbaum, R. L. & Ellis, C. E. Alzheimer’s disease and Parkinson’s disease. *N. Engl. J. Med.* **348**, 1356–1364 (2003).

2. Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. *Mov. Disord.* **30**, 1591–1601 (2015).

3. Killinger, B. A., McNaughton, K. R. & Jenner, P. Non-motor features of Parkinson disease. *Nat. Rev. Neurosci.* **18**, 435–450 (2017).

4. Stokholm, M. G. et al. Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. *Ann. Neurol.* **79**, 940–949 (2016).

5. Li, J. Y. et al. Lewy bodies in grafts in subjects with Parkinson’s disease suggest host-to-graft disease propagation. *Nat. Med.* **14**, 501–503 (2008).

6. Luk, K. C. et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* **338**, 949–953 (2012).

7. Hiltunen, D. et al. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. *Acta Neuropathol.* **127**, 235–241 (2014).

8. Holmquist, S. et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. *Acta Neuropathol.* **128**, 805–820 (2014).

9. Kim, S. et al. Transneuronal propagation of pathologic alpha-synuclein from the huro to the brain models Parkinson’s disease. *Neuron* **103**, 627–641 (2019).

10. Luk, K. C., McNaughton, K. R. & Jenner, P. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* **338**, 949–953 (2012).

11. Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. *Lancet Neurol.* **17**, 618–628 (2018).

12. Pourbozorg, M. et al. The verum form appendix impacts the risk of developing Parkinson’s disease. *Sci. Transl. Med.* **10**, eaar5280 (2018).

13. Dunn, W. A. Jr Studies on the mechanisms of autophagy: maturation of the autophagic vacuole. *J. Cell Biol.* **110**, 1935–1945 (1990).

14. Xilouri, M., Brekk, O. R. & Stefani, L. Autophagy and alpha-synuclein: relevance to Parkinson’s disease and related synucleopathies. *Mov. Disord.* **31**, 178–192 (2016).

15. Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson’s disease. *Science* **302**, 819–822 (2003).

16. Rubinsztain, D. C. The roles of intracellular protein-degradation pathways in neurodegeneration. *Nature* **443**, 780–786 (2006).

17. Dehaz, B. et al. Pathogenic lysosomal depletions in Parkinson’s disease. *J. Neurosci.* **30**, 12535–12544 (2010).

18. Baetens, J. et al. Glucocerebrosidase deficiency enhances cell-to-cell transmission of alpha-synuclein. *Nat. Commun.* **5**, 4775 (2014).

19. Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell* **166**, 37–52 (2016).

20. Giagne, E. et al. Age-dependent dopaminergic neurodegeneration and impairment of the autophagy-lysosomal pathway in LRRK2-deficient mice. *Neuron* **96**, 796–807 (2017).

21. Minakaki, G. et al. Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. *Autophagy* **14**, 98–119 (2018).

22. Danzer, K. M. et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. *Mol. Neurodegener.* **7**, 42 (2012).

23. Chang, D. et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. *Nat. Genet.* **45**, 1511–1516 (2017).

24. Aflaki, E., Westbroek, W. & Siddrnan, E. The complicated relationship between Gaucher disease and Parkinsonism: insights from a rare disease. *Neuron* **93**, 737–746 (2017).

25. Glaab, E. & Schneider, R. Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson’s disease. *Neurobiol. Dis.* **74**, 1–13 (2015).

26. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. *N. Engl. J. Med.* **361**, 1651–1661 (2009).

27. Schapsanz, J. et al. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. *Hum. Mol. Genet.* **23**, 4201–4214 (2014).
60. Chen, X. et al. Parkinson’s disease-linked D620N VPS35 knockin mouse manifests tau neuropathology and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. USA 106, 5765–5774 (2009).

61. Molochnikov, I. et al. A molecular signature in blood identifies early Parkinson’s disease. Mol. Neurodegener. 7, 26 (2012).

62. Michel, P. P., Hirsch, E. C. & Hunot, S. Understanding dopaminergic cell death pathways in Parkinson’s disease. Neuroreport 90, 675–691 (2016).

63. Kordower, J. H. et al. Development control of ULK1 activation by NDP52 and TBK1 during selective autophagy. Mol. Cell 74, 347–362 (2019).

64. Blaudin de The, F. X. et al. Neuroprotective transcription factors in animal models of Parkinson disease. Neural Plast. 2016, 6097107 (2016).

65. Nouri, N. & Awatramani, R. A novel floor plate boundary defined by adjacent En1 and Dlx1 microdomains distinguishes midbrain dopamine and mesencephalic dopaminergic neurons. Dev. Neurobiol. 84, 914–927 (2017).

66. Sherf, O. et al. Otz2 requires Lmx1b to control the development of mesodiencephalic dopaminergic neurons. PLoS ONE 10, e0139697 (2015).

67. Ellinghaus, D. et al. Association between variants of PRDM1 and NDP52 and Crohn’s disease, based on exome sequencing and functional studies. Gastroenterology 145, 339–347 (2013).

68. Olgiati, S. et al. DNAJC6 Mutations Associated With Early-Onset Parkinson’s Disease. Ann. Neurol. 79, 244–256 (2016).

69. Vilumlsen, M. et al. Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977-2014. Gut 68, 18–24 (2019).

70. Hui, K. Y. et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease. Sci. Transl. Med. 10, eaai7795 (2018).

71. Chassaing, B. et al. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 104, 15.25.1–15.25.14 (2014).

72. Grathwohl, S. et al. Experimental colitis drives enteric alpha-synuclein accumulation and triggering alpha-synuclein-like brain pathology. bioRxiv https://doi.org/10.1101/505164 (2019).

73. Kishimoto, Y. et al. Chronic Mild gut inflammation accelerates brain neuropathology and motor dysfunction in alpha-synuclein mutant mice. Neuroinflammation 21, 239–249 (2019).

74. Benskey, M. J. et al. Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants. Mol. Ther. 23, 488–500 (2015).

75. Benskey, M. J. & Manfredsson, F. P. Gene therapy of the peripheral nervous system: the enteric nervous system. Methods Mol. Biol. 1382, 263–274 (2016).

76. Gar-On, Z. et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 80, 1606–1610 (2013).

77. Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455–463 (2012).

78. Li, Y. I. et al. Prioritizing Parkinson’s disease genes using population-scale transcriptomic data. Nat. Commun. 10, 994 (2019).

79. Lang, C. et al. Single-cell sequencing of mouse from experimental colitis. Autophagy 9, 1188–1200 (2013).

80. Liu, Y. et al. Autosis is a Na+-K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc. Natl Acad. Sci. USA 110, 20364–20371 (2013).

81. Marino, G. et al. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 15, 81–94 (2014).

82. Denton, D. et al. Autophagy, not apoptosis, is essential for midgut cell death in Drosophila. Curr. Biol. 19, 1741–1746 (2009).

83. Shen, T. et al. Erbin exerts a protective effect against inflammatory bowel disease by suppressing autophagic cell death. Oncotarget 9, 12035–12049 (2018).

84. Devos, D. et al. Colonic inflammation in Parkinson’s disease. Neurobiol. Dis. 50, 42–48 (2013).

85. Xia, Y. et al. The macrophage-specific V-ATPase subunit ATP6V0D2 restricts inflammasome activation and bacterial infection by facilitating autophagosome-lysosome fusion. Autophagy 15, 960–975 (2019).

86. Sitter, D. A. et al. Parkin and PINK1 mitigate STING-induced inflammation. Nat. Neurosci. 21, 372–382 (2018).

87. Kauppinen, A. et al. Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 25, 1939–1948 (2013).

88. Naz, S. et al. Transcriptome meta-analysis identifies immune signature comprising of RNA binding proteins in ulcerative colitis patients. Cell Immunol. 334, 42–48 (2018).

89. Swidnicka-Sierjeogo, A. K. et al. Chronic inflammation initiates multiple forms of K-Ras-dependent mouse pancreatic cancer in the absence of TP53. Oncogene 36, 3149–3158 (2017).

90. Pyne, N. J. et al. Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. Adv. Biol. Regul. 60, 151–159 (2016).

91. He, Y. et al. p38 MAPK inhibits autophagy and promotes microglial inflammatory responses by phosphorylating ULKI. J. Cell Biol. 217, 315–338 (2018).

92. Sotilzenberg, E. et al. Role for neuronal alpha-synuclein in gastrointestinal immunity. J. Innate Immun. 9, 456–463 (2017).

93. Beatman, E. L. et al. Alpha-synuclein expression restricts RNA viral infections in the brain. J. Virol. 90, 2767–2782 (2015).

94. Chen, S. G. et al. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Sci. Rep. 6, 34477 (2016).

95. Diep, D. et al. Library-free methylation sequencing with bisulphite conversion: a comparison across serotypes and capsid mutants. Proc. Natl Acad. Sci. USA 110, 3465–3471 (2013).

96. Ritchie, M. E. et al. linnaemus differences in expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
Author contributions
J.G. contributed to experimental design and computational analyses. P.L. was involved in DNA methylation sequencing data preprocessing and RNA-seq analysis. L.M. designed the bisulfite padlock probes in humans and mice and contributed to DNA methylation data preprocessing. BK isolated nucleic acids from appendix, performed neuronal nuclei aggregation in the colon of a transgenic mouse model of Parkinson disease, and contributed to bisulfite padlock probe library preparation. E.E. and W.C. contributed to bisulfite padlock probe library preparation. N.M.K. and E.K.P.M. contributed to the experiments involving rAAV α-syn overexpression in mice. M.G.R., C.S.P., and M.B. were involved in the gut inflammation mouse model. V.L. was involved with study design and overseeing the experiments. The manuscript was written by V.L. and S.L. and commented on by all authors.

Ethics approval
For the human tissue studies, the study protocol was ethically approved by the institutional review board at the Van Andel Research Institute (IRB #15025). For the gut inflammation mouse model, the animal experiments were endorsed by a Roche internal review board and approved by the local animal welfare authorities in Canton Basel-Stadt, Basel, Switzerland. The experiment using rAAV vectors in mice was performed in accordance and with ethical approval of the Michigan State University Institutional Animal Care & Use Committee guidelines (AUF 08-16-148-00).

Competing interests
N.M., R.L., C.R., I.V., and M.B. are or were full-time employees at Roche and they own Roche stock/stock options.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-25474-x.

Peer review information Nature Communications thanks Beate Ritz, Moshe Szyf and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Published online: 21 June 2021

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements
The authors thank Family Farmer Foundation, the Van Andel Research Institute Flow Cytometry, Genomics, Bioinformatics and Biostatistics, and Pathology Cores. We also thank the CAMH Sequencing Facility. We thank all organ donors and their families for their support of our research. We thank the Oregon Brain Bank, Spectrum Health Universal Biorepository, Parkinson’s UK Brain Bank, the NIH NeuroBioBank, and the Michigan Brain Bank for the tissue provided. We are also grateful for the proteomics services provided by Dr. Eric Spooner at the Whitehead Institute Proteomics Core Facility. We appreciate the manuscript review and recommendations provided by Dr. Patrik Brandin. We thank L. Sychterz and C. Zandel at Roche for their technical support with the DSS colitis paradigm and tissue processing. N.M. was funded by the Roche Postdoctoral Fellowship Program. Data were generated as part of the PsyChENCODE Consortium supported by: U01MH103339, U01MH103865, U01MH103392, U01MH103340, U01MH103346, R01MH105472, R01MH94714, R01MH105898, R21MH102791, R21MH105881, R21MH103877, and P50MH106934 awarded to Schahram Akbarian (Icahn School of Medicine at Mount Sinai), Gregory Crawford (Duke), Stella Dracheva (Icahn School of Medicine at Mount Sinai), Peggy Farnham (USC), Mark Gerstein (Yale), Daniel Geschwind (UCLA), Thomas M. Hyde (LIBD), Andrew Jaffe (LIBD), James A. Knowles (USC), Chunyu Liu (UC), Dalila Pinto (Icahn School of Medicine at Mount Sinai), Nenad Sestan (Yale), Pamela Sklar (Icahn School of Medicine at Mount Sinai), Matthew State (UCSF), Patrick Sullivan (UNC), Flora Vaccarino (Yale), Kevin Weissman (UChicago) and Peter Zandi (JHU). VL is supported by grants from the Department of Defense (W81XWH1810512), the National Institute of Neurological Disorders and Stroke (1R21NS112614-01), and a Gisyb & Friends vs Parky Award. Vector work (FPM) was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (5801DK108798).

© The Author(s) 2021